Traditionally, a minister orders an opinion from a health agency. We give it to him, he takes note of it and then decides to follow it, or not. The one made, Thursday, June 3, by the High Authority for Health (HAS), which recommends to the government the extension of vaccination to all young people over 12 years old will not be followed… because it was preceded.
President Emmanuel Macron, traveling in the Lot, announced on Wednesday afternoon that young people aged 12 to 18 could be vaccinated from June 15. Then the Minister of Health, Olivier Véran, specified, at the “8:00 p.m.” of TF1, that this vaccination ” will be done on a voluntary basis and with the parents’ agreement ”.
In the absence of an announcement, the HAS therefore provides text explanation. And she’s going to be precious. Because as the pharmacology professor Mathieu Molimard indicates, “This is the first time in France that we are going to vaccinate young people above all to protect their parents and grandparents. It’s a paradigm shift. It deserves some clarification ”.
The HAS opinion follows the provisional authorization granted, Friday, May 28, by the European Medicines Agency (EMA) to the Comirnaty vaccine from the Pfizer laboratory, for use in young people from 12 years of age. The US Food and Drug Administration (FDA) made the same decision on May 10, and on May 12, Americans began immunizing their adolescents.
HAS experts were able to take advantage of these various examinations, the first feedback from the field and the results of the clinical trial carried out by the Pfizer laboratory over 12-15 year olds. Finally, they are based on a 170-page report made by the agency’s technical committee on vaccination, which scans all registers: virological, epidemiological, pharmacological and ethical. The HAS examines the various benefits offered by the vaccine to adolescents and the possible risks that it could make them run.
On the risk side, experts have few doubts. Clinical trials have not shown any severe side effects that may cause concern. “We observe a significant reactogenicity, slightly higher in 12-15 year olds than in 16-25 year olds, but nothing serious, indicates pharmacologist Antoine Pariente, member of the AME pharmacovigilance risk assessment committee. With the campaigns already launched, we have taken a step back and have not detected any particular signal. ”
You have 69.35% of this article left to read. The rest is for subscribers only.